Alight, Inc. / Delaware
No enriched coverage for $ALIT in the last 7 days.
No SEC Form 4 filings for $ALIT in the last 30 days.
See all $ALIT insider activity →Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
Alight (ALIT) said it partnered with Spring Health to integrate Spring Health’s AI-native mental health services into the Alight Worklife benefits platform. The platform supports over 210 million annual interactions. Alight said the goal is earlier access during events like open enrollment and leave. JAMA Network Open research cited faster recovery for Spring Health members.
Alight (NYSE:ALIT) reported Q2 revenue of $511 million, beating Wall Street expectations, with adjusted EBITDA of $92 million and free cash flow above estimates. However, recurring revenue fell 4.3% and adjusted EPS dropped to $0.91 from $2.09. Q3 guidance calls for $469 million to $479 million revenue and adjusted EBITDA of $55 million to $61 million.
Recent ALIT coverage spans earnings, corporate actions and regulation.
Strategic partnership may broaden Alight's service offering and drive growth.
Partnership expands Alight Worklife’s mental health offering, potentially improving employer engagement and member utilization.
The article frames a near-term earnings beat masking a deteriorating core recurring revenue trend, with Q3 guidance implying continued margin pressure.
The guidance miss is the primary driver of the selloff, despite Q2 revenue and profitability beating estimates.
The print is a mixed beat on revenue and non-GAAP EPS, but the forward revenue guide and lingering renewal drag are likely the dominant driver for near-term positioning.
alphai scores every news story that mentions ALIT with an AI model for sentiment and relevance, and aggregates insider trades from Alight, Inc. / Delaware's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.
3 min readAlight (ALIT) said it partnered with Spring Health to integrate Spring Health’s AI-native mental health services into the Alight Worklife benefits platform. The platform supports over 210 million annual interactions. Alight said the goal is earlier access during events like open enrollment and leave. JAMA Network Open research cited faster recovery for Spring Health members.
3 min readAlight (NYSE:ALIT) reported Q2 revenue of $511 million, beating Wall Street expectations, with adjusted EBITDA of $92 million and free cash flow above estimates. However, recurring revenue fell 4.3% and adjusted EPS dropped to $0.91 from $2.09. Q3 guidance calls for $469 million to $479 million revenue and adjusted EBITDA of $55 million to $61 million.
4 min readAlight (NYSE: ALIT) shares fell about 17% after the company issued weak forward guidance. Although its second-quarter revenue and adjusted profitability beat expectations, investors focused on a 3.2% year-over-year sales decline and a third-quarter revenue outlook about 5.5% below analyst estimates, with a midpoint of $2.09 billion. Full-year revenue and adjusted EBITDA forecasts also missed consensus.
4 min readAlight (NYSE: ALIT) reported Q2 CY2026 revenue of $511 million, down 3.2% year on year but above Wall Street expectations, and non-GAAP EPS of $0.91, 20% above consensus. Next-quarter revenue guidance was $474 million, 5.5% below estimates. Management cited stronger project revenue, but recurring revenue and renewals remain pressured.
5 min readAlight (NYSE:ALIT) reported Q2 CY2026 revenue of $511 million, down 3.2% year on year but 2.8% above Wall Street estimates. Non-GAAP EPS was $0.91, up 20% versus consensus. Guidance for next quarter revenue was $474 million, 5.5% below estimates, and the stock fell 9.1% to $15.58.
4 min readRajgopal Kausik purchased 38 shares of Alight, Inc. / Delaware (ALIT) at $20.53 on 2025-12-15.
2 min readAlight, Inc. / Delaware (ALIT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-3.1 2 alit-20260629xexx31xalight.htm EX-3.1 Document Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF ALIGHT, INC. Alight, Inc., a corporation organized and existing under the laws of the State of Delaware (the “ Corporation ”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The prese
2 min readAlight (NYSE: ALIT) shares rose 1.4% to about $0.56 after DA Davidson reiterated a Buy rating and $2.00 price target. The move followed Alight’s 1-for-20 reverse stock split to maintain listing compliance. DA Davidson cited management changes and said 2026 is a transition year, after Alight’s Q1 2026 results beat expectations.
4 min readAlight, Inc. / Delaware (ALIT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. alit-20260610 0001809104 FALSE Alight, Inc. / Delaware 0001809104 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________ FORM 8-K __________________________________________ CURRENT REPORT Pursuant t
2 min read
